Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Low-flow low-gradient aortic stenosis: aortic valve area estimated by continuity equation versus projected aortic valve area
Session:
Sessão de Posters 39 - Fenótipos de estenose aórtica, imagem e fisiopatologia
Speaker:
Adriana Henriques Silva
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
15. Valvular Heart Disease
Subtheme:
15.3 Valvular Heart Disease – Diagnostic Methods
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Adriana Silva; Paula Fazendas; João Pais; Rafael Viana; Liliana Brochado; Oliveira Baltazar; Isabel João; Hélder Pereira; Ana Almeida
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Introduction: Stratifying severity in low-flow low-gradient (LFLG) aortic stenosis (AS) can be clinically challenging. The projected aortic valve area (AVAproj), estimating aortic valve area (AVA) at normal transvalvular flow, has been proposed as a more reliable marker of true stenosis. The TOPAS study previously showed the prognostic relevance of AVAproj.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Propose: To compare AS severity classification based on AVA estimated by continuity equation at peak dobutamine stress echocardiography (AVA-CE) versus AVAproj and evaluate their prognostic value in predicting the composite outcome of aortic valve replacement (AVR) or all-cause mortality at 2 years.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Methods: Single-center retrospective study including individuals with AS who underwent dobutamine stress echocardiography (DSE). Reclassification rates were analyzed. Logistic regression models were constructed to assess the association of AS severity with the composite outcome.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Results: From a total of 57 patients (pts) with AS submitted to DSE, we included 24 pts with transvalvular flow rate at peak stress<250 mL/s. </span></span><span style="font-size:12pt"><span style="font-family:Calibri">The mean age was 69±10 years, 83% were male. Echocardiographic parameters are summarized in Table 1.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">AVA-CE was significantly different from the AVAproj (p=0.044). When using categorical severity classification (severe vs. moderate), 22 pts (92%) were classified as having true severe stenosis with AVA-CE and 14 pts (58%) were classified as having severe stenosis with projected AVA. </span></span><span style="font-size:12pt"><span style="font-family:Calibri">Between rest and AVA-CE, only 1 pt changed classification (1 from severe to moderate) (p=1.000). When comparing AVAproj to AVA-rest, 9 initially classified as severe were reclassified as moderate (p=0.004). When comparing AVAproj to AVA-CE, 8 classified as moderate by AVAproj were classified as severe by AVA-CE (p=0.008).</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Two logistic regression models were developed to predict the combined endpoint of AVR or death at 2 years. The first model, including rest LVEF and AVA-CE severity classification, did not reach statistical significance overall (p=0.056), and neither variable was individually predictive. The second model, which included rest LVEF and AVAproj classification, was statistically significant (p=0.005), with AVAproj classification showing a strong association with the outcome (OR 16.17, IC 95% 1,29–301,81, p=0.050). </span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Conclusion: AVAproj differed significantly from AVA-CE and demonstrated superior prognostic value. These findings support the clinical relevance of including AVAproj in the evaluation of AS.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site